NanoEcho’s core values
Through responsibility, commitment, focus, and reliable delivery, we create value.
These core values not only represent our principles but also our commitment and endeavor to live up to them in every task we undertake. Our goal is to let these values guide us in all our tasks.
Responsibility: We take responsibility for our commitments and tackle challenges with determination. We take ownership and deliver as promised. We speak truthfully and, when uncertain, offer clarity by presenting facts. Through openness, we build trust.
Commitment: With a burning passion for our customers and our mission, we have strong faith in our solution, our product, and our capabilities. We engage collaboratively with customers, colleagues, owners, suppliers, and stakeholders. Together, we strive to meet high expectations.
Focus: With courage and determination, we steer towards our goal. By daring to prioritize, we create value for our customers. We remain focused on fulfilling our customers’ needs.
Delivery: We work to create value, to deliver to our customers, and to keep our promises. Through knowledge, innovation, and collaboration, we ensure quality-driven deliveries.
Management and board
The management consists of people with solid experience and knowledge in medical technology and commercialization. There is also a background of successfully driving products from idea stage to successful launches
Board of directors
CEO
Holdings: 550 330 shares, 250 330 warrants of series TO1 and 1 750 000 warrants through incentive program
Linda Persson has a PhD in medical technology and has extensive experience from several leading positions with focus on product development. She comes most recently from a senior role in the strategy and business development department at E.ON. Before that, Linda also held influential positions at other companies, such as Baxter and Sony
CTO
Holdings: 234 891 shares, 140 320 warrants of series TO1 and 1 750 000 warrants through incentive program
Magnus Santesson is educated at Lund University in computer science. Magnus has solid experience as a program and project manager for technical global development projects in fast-moving consumer goods and medical technology. He co-founded and developed Mobytech Consulting, which had 28 employees before it was sold to a French consulting company.
Henrik Ljung
CFO
Holdings: 121 953 shares (via bolaget Ljung & Winbladh AB)
Henrik Ljung has an MBA and has several years of experience as the CFO of Cerdo Bankpartner AB, Acconeer AB, Ballingslöv AB, Sardus AB, and Malmöhus Invest AB, among others.
Dr. Ulrika Axelsson
Clinical Director
Holdings: 104 759 shares, 47 617 warrants of series TO1 and 562 500 warrants through incentive program
Ulrika Axelsson has a Ph.D. in Immunotechnology and has experience in running clinical trials. Most recently she had a position as business coach at SmiLe Life Science Incubator. Before that, Ulrika worked at PainDrainer AB and in leading positions at CREATE Health Translational Cancer Center, with the aim of commercializing research in oncology.
CEO
Holdings: 550 330 shares, 250 330 warrants of series TO1 and 1 750 000 warrants through incentive program
Linda Persson has a PhD in medical technology and has extensive experience from several leading positions with focus on product development. She comes most recently from a senior role in the strategy and business development department at E.ON. Before that, Linda also held influential positions at other companies, such as Baxter and Sony
CTO
Holdings: 234 891 shares, 140 320 warrants of series TO1 and 1 750 000 warrants through incentive program
Magnus Santesson is educated at Lund University in computer science. Magnus has solid experience as a program and project manager for technical global development projects in fast-moving consumer goods and medical technology. He co-founded and developed Mobytech Consulting, which had 28 employees before it was sold to a French consulting company.
Henrik Ljung
CFO
Holdings: 121 953 shares (via Ljung & Winbladh AB)
Henrik Ljung has an MBA and has several years of experience as the CFO of Cerdo Bankpartner AB, Acconeer AB, Ballingslöv AB, Sardus AB, and Malmöhus Invest AB, among others.
Dr. Ulrika Axelsson
Clinical Director
Holdings: 104 759 shares, 47 617 warrants of series TO1 and 562 500 warrants through incentive program
Ulrika Axelsson has a Ph.D. in Immunotechnology and has experience in running clinical trials. Most recently she had a position as business coach at SmiLe Life Science Incubator. Before that, Ulrika worked at PainDrainer AB and in leading positions at CREATE Health Translational Cancer Center, with the aim of commercializing research in oncology.
Board of directors
Holdings: 62 536 511 shares and 31 603 156 warrants of series TO1 (via Quiq Holding AB and via related/legal entities)
Education and Background: Master’s studies in Electrical Engineering at Chalmers University of Technology. Studies in the Bachelor of Economics program at the Gothenburg School of Economics. Experienced serial entrepreneur with several successful exits. 25 years of experience as CEO at Exertis Nordics AB, of which the last 7 years were within a publicly listed group. Currently active as an investor and advisor.
Other Current Assignments: Chairman of the Board at Postery AB, Renable AB, Admazing AB, and Brink Commerce AB, as well as a board member of IRLAB Therapeutics AB, Integrative Research Laboratories Sweden AB, Quiq Holding AB, CapTech Holding AB, JOSI Holding AB, JHD Holding AB, Tura Group AB, Flower Infrastructure Technologies AB, Chilimobil Sweden AB, DB24 AB, and Hilke Collection AB.
Holdings: 1 904 760 shares and 476 190 warrants of series TO1 (via bolaget Hager Consulting AB)
Education and Background: PhD in Immunotechnology and MSc in Chemical Engineering from LTH, and Pharma-MBA from Falconbury. Ann-Christin has extensive experience in founding companies within life sciences. She has previously been the CEO of PainDrainer AB, SenzaGen AB, DiaProst AB, Cantargia AB, and XImmune AB. Ann-Christin has worked as Investment Director at LU Bioscience and VP Business Development at Alligator Bioscience AB.
Other Current Assignments: Advisor to start-up companies and board member of SenzaGen AB, Lead Biologics International AB, Avena Partners AB, and Hager Consulting AB.
Holdings: 3 566 664 shares and 216 664 warrants of series TO1 (via Nosterix AB)
Education and Background: Åke has had a long career in executive roles as CFO and CEO in various manufacturing industries with an international focus. Åke holds an Executive MBA from SIMI Copenhagen. He currently offers interim management services and advisory roles through his own company.
Other Current Assignments: Active as a business coach for Produktionsänglar, Södertälje Science Park, and Senior Business Advisor at SMILE Incubator, as well as a board member of Nosterix AB.
Holdings: 1 309 520 shares and 595 235 warrants of series TO1
Education and Background: Tord holds a Ph.D. in tumour immunology from Lund University and has more than 15 years of international experience in senior positions within the pharmaceutical industry, primarily in R&D but also in commercial roles.
Other Current Assignments: CEO of Alzinova AB, as well as founder and CEO of TL MedVision AB.
Chairman of the board since 2022
Holdings: 62 536 511 shares and 31 603 156 warrants of series TO1 (via Quiq Holding AB and via related/legal entities)
Education and Background: Master’s studies in Electrical Engineering at Chalmers University of Technology. Studies in the Bachelor of Economics program at the Gothenburg School of Economics. Experienced serial entrepreneur with several successful exits. 25 years of experience as CEO at Exertis Nordics AB, of which the last 7 years were within a publicly listed group. Currently active as an investor and advisor.
Other Current Assignments: Chairman of the Board at Postery AB, Renable AB, Admazing AB, and Brink Commerce AB, as well as a board member of IRLAB Therapeutics AB, Integrative Research Laboratories Sweden AB, Quiq Holding AB, CapTech Holding AB, JOSI Holding AB, JHD Holding AB, Tura Group AB, Flower Infrastructure Technologies AB, Chilimobil Sweden AB, DB24 AB, and Hilke Collection AB.
Dependent in relation to the major shareholders and independent in relation to the Company.
Member of the board since 2022
Holdings: 1 904 760 shares and 476 190 warrants of series TO1 (via Hager Consulting AB)
Education and Background: PhD in Immunotechnology and MSc in Chemical Engineering from LTH, and Pharma-MBA from Falconbury. Ann-Christin has extensive experience in founding companies within life sciences. She has previously been the CEO of PainDrainer AB, SenzaGen AB, DiaProst AB, Cantargia AB, and XImmune AB. Ann-Christin has worked as Investment Director at LU Bioscience and VP Business Development at Alligator Bioscience AB.
Other Current Assignments: Advisor to start-up companies and board member of SenzaGen AB, Lead Biologics International AB, Avena Partners AB, and Hager Consulting AB.
Independent in relation to the Company and to major shareholders.
Member of the board since 2023
Holdings: 3 556 664 shares and 216 664 warrants of series TO1 (via Nosterix AB)
Education and Background: Åke has had a long career in executive roles as CFO and CEO in various manufacturing industries with an international focus. Åke holds an Executive MBA from SIMI Copenhagen. He currently offers interim management services and advisory roles through his own company.
Other Current Assignments: Active as a business coach for Produktionsänglar, Södertälje Science Park, and Senior Business Advisor at SMILE Incubator, as well as a board member of Nosterix AB.
Independent in relation to the Company and to major shareholders.
Member of the board since 2023
Holdings: 1 309 520 shares and 595 235 warrants of series TO1
Education and Background: Tord holds a Ph.D. in tumour immunology from Lund University and has more than 15 years of international experience in senior positions within the pharmaceutical industry, primarily in R&D but also in commercial roles.
Other Current Assignments: Operational role as Vice President and Global Head of Clinical Development at LEO Pharma in Denmark and board member of TL Medvision AB.
Independent in relation to the Company and to major shareholders.
Dependent in relation to the major shareholders and independent in relation to the Company.
Independent in relation to the Company and to major shareholders.
Independent in relation to the Company and to major shareholders.
Independent in relation to the Company and to major shareholders.
The Nomination Committee’s proposal for Chairman of the Board
Björn Larsson
Education and Background: MSc in Engineering from Chalmers University of Technology. Björn Larsson brings a wealth of experience from leadership roles in the global pharmaceutical, biotech, medical technology, and diagnostics sectors, such as AstraZeneca, Novo Nordisk and Medtronic, as well as founder CEO, and board positions in startups and scaleups, for example CEO Observe Medical, CEO RLS Medical, CEO Medfield Diagnostics, and Chairman at Alzinova AB. Bjorn has also been investment manager Life science for GU Ventures.
Current assignments: Interim Executive advisor to Acorai AB, Board member Industry Commons foundation, Chairman of APNC Sweden AB, Strategic advisor to ReThink Capital AB, Business advisor to MultiD Analyses AB and partner and investor at CVX Ventures AS. Independent consultant (with his company BearInMind AB) advising startups and scaleups, with recent focus on Health data and Data driven innovations.
Björn Larsson
Education and Background: MSc in Engineering from Chalmers University of Technology. Björn Larsson brings a wealth of experience from leadership roles in the global pharmaceutical, biotech, medical technology, and diagnostics sectors, such as AstraZeneca, Novo Nordisk and Medtronic, as well as founder CEO, and board positions in startups and scaleups, for example CEO Observe Medical, CEO RLS Medical, CEO Medfield Diagnostics, and Chairman at Alzinova AB. Bjorn has also been investment manager Life science for GU Ventures.
Current assignments: Interim Executive advisor to Acorai AB, Board member Industry Commons foundation, Chairman of APNC Sweden AB, Strategic advisor to ReThink Capital AB, Business advisor to MultiD Analyses AB and partner and investor at CVX Ventures AS. Independent consultant (with his company BearInMind AB) advising startups and scaleups, with recent focus on Health data and Data driven innovations.
